Triplet Therapy Doubles Survival in HER2-Positive Breast Cancer Patients with Leptomeningeal Metastasis
Key Insights
A phase II study of 17 patients with HER2-positive breast cancer (search) and leptomeningeal metastasis (search) showed median overall survival increased from 4.4 months to 10 months with tucatinib, trastuzumab, and capecitabine combination therapy.
The treatment demonstrated clinical benefit beyond survival extension, with 41% of patients alive at 18 months and seven of 12 evaluable patients showing improved neurologic deficits.
The triplet regimen achieved a median of seven months before central nervous system progression, representing a meaningful advance for patients who historically have had limited treatment options.
A combination of tucatinib, trastuzumab, and capecitabine has demonstrated promising results in treating patients with HER2-positive breast cancer (search) and leptomeningeal metastasis (search), according to results from the phase II TBCRC049 study published in Nature Cancer. The 17-patient study showed median overall survival increased from a historical average of 4.4 months to 10 months, with 41% of patients still alive at the 18-month mark.
Addressing a Critical Unmet Need
Leptomeningeal metastasis (search) presents unique treatment challenges that have historically left patients with few therapeutic options. The condition is difficult to treat primarily because the blood-brain barrier may block drugs from reaching the spinal fluid, where the metastatic cells are found. Additionally, leptomeningeal metastasis is not a solid tumor, but is made up of metastatic cells living in fluid, making them more difficult to target.
"The combination achieved a clinically meaningful improvement in overall survival compared to historical controls," said lead author Rashmi Murthy, MD, Associate Professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. "For these patients, who often face limited treatment options, our results represent a step forward, offering new hope in how we treat and manage leptomeningeal metastasis (search)."
Study Design and Treatment Protocol
The single-arm, nonrandomized, multiphase study enrolled patients at four sites. Eligible patients were at least 18 years old with histologically proven metastatic HER2 (search)-positive breast carcinoma and newly diagnosed leptomeningeal metastasis (search). The treatment regimen consisted of 21-day cycles of oral tucatinib (300 mg) twice daily, plus oral capecitabine (1,000 mg/m²) twice daily on days 1 to 14 and intravenous trastuzumab (6 mg/kg) on day 21.
The therapeutic approach combines three distinct mechanisms of action. Tucatinib is a targeted therapy that blocks the HER2 (search) protein, which helps some breast cancers grow. Trastuzumab is a targeted antibody that attaches to the HER2 protein on cancer cells and helps the immune system destroy them. Capecitabine is a chemotherapy that turns into fluorouracil in the body to eliminate fast-growing cancer cells.
Clinical Outcomes and Symptom Improvement
Beyond survival benefits, the study demonstrated meaningful improvements in disease control and neurologic function. Disease progression stalled, with a median of 7 months before central nervous system progression. Seven of 12 evaluable patients also had improved neurologic deficits, representing a significant advance in symptom management.
"In addition to encouraging survival outcomes, throughout this study we observed improvements in neurologic symptoms," said co-lead author Barbara O'Brien, MD, Associate Professor of Neuro-Oncology at MD Anderson. "Treatments for breast cancer leptomeningeal metastasis (search) have historically focused on stabilizing disease rather than improving symptoms, making these findings particularly meaningful and encouraging."
Safety Profile and Tolerability
Side effects of the triplet included diarrhea, nausea, vomiting, hand-foot syndrome, and liver function test elevation. Most adverse effects improved or resolved with appropriate care and dose modifications. One patient experienced alanine aminotransferase elevation after one cycle, which led to discontinuation of the combination, and symptoms resolved after 1 month.
Study Limitations and Future Directions
Study limitations include early termination due to slow accrual following U.S. Food and Drug Administration approval of the combination therapy. Additionally, leptomeningeal metastasis (search) from HER2 (search)-positive metastatic breast cancer is rare, resulting in limited published data. As a result, the study design was informed by the small amount of available retrospective evidence.
The authors concluded, "This prospective study suggests clinical benefit with a systemic regimen for HER2 (search)-positive leptomeningeal metastasis (search) including objective responses, improved symptoms, and extended survival."